Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temsirolimus with FLT-PET and FDG-PET evaluation in pretreated metastatic renal cell carcinoma
NL-OMON33063Phase 2Recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Aug 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temsirolimus in renal cell carcinoma (RCC), sponsored by Radboud University Medical Center. Primary endpoint: Progression-free survival. Started Aug 2009; status: recruiting.
02
Drugs
temsirolimus
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NL-OMON33063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33063.